ResMed Inc. (LON:0KW4)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 30.86B |
| Revenue (ttm) | 3.76B |
| Net Income (ttm) | 1.02B |
| Shares Out | n/a |
| EPS (ttm) | 6.94 |
| PE Ratio | 30.18 |
| Forward PE | 25.54 |
| Dividend | 1.64 (0.59%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 420 |
| Average Volume | 84 |
| Open | 275.36 |
| Previous Close | 275.92 |
| Day's Range | 271.50 - 279.36 |
| 52-Week Range | 199.71 - 281.49 |
| Beta | 0.77 |
| RSI | 72.98 |
| Earnings Date | Jul 31, 2025 |
About Aspen Technology
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on de... [Read more]
Financial Performance
In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial StatementsNews
Top 15 High-Growth Dividend Stocks For July 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, ...
ResMed: A Mixed Bag for Investors Amid Rising Competition
ResMed: A Sleeping Giant Hiding In Plain Sight
ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's s...
Top 15 High-Growth Dividend Stocks For June 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, thoug...
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the ...
Top 15 High-Growth Dividend Stocks To Consider For May 2025
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming V...
Resmed Acquires VirtuOx
Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, ...
Billion-dollar medical start-ups say Trump could force a US move
Nanosonics chief executive Michael Kavanagh said the government should step in and help domestic development, a sentiment echoed by ResMed boss Mick Farrell.
We reaffirmed our tariff relief in 2008 and 2009, we went back again 3 weeks ago, says Resmed CEO
Mick Farrell, Resmed CEO, joins 'Mad Money' host Jim Cramer to talk GLP-1s, the impact of tariffs, quarterly results, and more.
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
On Wednesday, ResMed Inc (NYSE: RMD) reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36 . Quarterly sales increased 8% year over year to $1.29 billion, which aligns wi...
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36.
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 300 points on Thursday. Shares of Texas Instruments Incorporated (NASDAQ: TXN) rose sharply during Thursday's session after the compa...
ResMed declares $0.53 dividend
ResMed: Cornering The Market In Sleep Solutions
‘Tariff-exempt’ ResMed boosts US manufacturing
Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not be subject to Donald Trump’s levies.
ResMed outlines Q4 2025 gross margin target of ~59.9% amid strong product launches
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
ResMed Inc. 2025 Q3 - Results - Earnings Call Presentation
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ASX 200 LIVE: Trump reportedly considering lower China tariffs; miners buoy sharemarket as iron ore climbs
Shares edge higher; Trump may wind down tariff rate on China; Tesla leaps 5pc; ResMed evades trade war blow; iron ore rallies, gold stocks bounce back.
A Look Ahead: ResMed's Earnings Forecast
ResMed (NYSE: RMD) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-23. Here's a quick overview of what investors should know before the release. Analysts are estimating that Re...
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experienc...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home ...